Special Issue

Pharmacogenetic Testing in Primary Care and Prevention

Message from the Guest Editors

The increasing implementation of pharmacogenetic (PGx) testing brings challenges and excitement. Like other testing applications in personalized and precision medicine, PGx testing is increasingly being used in healthy individuals and in patients with common, chronic diseases and to affect risk factors for cardiovascular disease and cancer. Can PGx testing be used for precision prescribing, and ultimately improve clinical outcomes in healthy populations and for primary and for secondary prevention in patients with conditions commonly managed in primary care -- like hypertension, hyperlipidemia, type 2 diabetes, and depression. This Special Issue focuses on the clinical application of pharmacogenetic testing in primary care and prevention contexts. It includes, but is not limited to, populationbased studies on genetic variation in the toxicity and efficacy of commonly used drugs, multi-omics studies for determining therapeutic and toxicity response, determination of epigenetic changes in drug response/resistance, and the implementation of pharmacogenetic testing results into routine clinical interactions.

Guest Editors

Dr. Latha Palaniappan

Dr. Sean P. David

Dr. Deepak Voora

Deadline for manuscript submissions

closed (1 November 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/82864

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

